No Result
View All Result
Saturday, December 14, 2019
MY ACCOUNT
PRO LOGIN
SUBSCRIBE
  • 🌎 Worldwide
    • 🇺🇸 U.S.
    • 🇨🇦 Canada
    • 🇬🇧 United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
Daily Marijuana Observer
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies
No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies
No Result
View All Result
Daily Marijuana Observer
No Result
View All Result
Home Health

GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients

PR Newswire by PR Newswire
May 28, 2019
in Canada, Doctors, Health, Investments, Marijuana Stocks, Patients, Press Releases
0
National Research Council of Canada Cannabis research

Photo Credit - Peregrine981 via Wikimedia

73
SHARES
ShareShare

OTTAWA, Ontario, May 28, 2019 /PRNewswire/ — GBS Global Biopharma, Inc. (“GBS Global”), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council (“NRC”) Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development. Because people are living longer around the world, the global chronic pain treatment market is expected to reach $105.9 billion by 2024.

“Bringing our chronic-neuropathic pain formulations into preclinical animal studies is an important milestone in the development of these patent-pending, time-released formulations,” said Dr. Andrea Small-Howard, Chief Science Officer and Director of GBS Global. “We are very fortunate to be working with Dr. Ellis on this important project because of his unique experience in developing novel animal models for studying pain therapies and his track record of publications on the efficacy of cannabinoid-based therapies. Dr. Ellis and his team have also been performing preclinical animal testing on the safety and efficacy of GBS Global’s Parkinson’s disease therapies, so we know that they are great collaborators.”

Providing sustained relief from chronic-neuropathic pain would bring quality of life to tens of millions of patients throughout the world who suffer from conditions such as fibromyalgia, spine compression-related neuropathy, post-herpetic neuropathy, diabetic peripheral neuropathy; as well as, cancer-related and HIV/AIDS-related neuropathies.

“The disease models that have been and are being developed at the NRC are designed to provide novel platforms for the initial screening of potential therapeutics,” said Dr. Ellis. “We have shown that these animal models can be used to test the effectiveness of cannabinoids, and we are looking forward to evaluating how the results compare to GBS Global’s time-released formulations.”

GBS Global’s orally-administrated, time-released, chronic-neuropathic pain formulations use nanotechnology to encapsulate the cannabis-based ingredients within a polymeric matrix to: 1) avoid digestion of the active ingredients; 2) target their absorption; 3) prolong blood circulation; and 4) provide a slow and steady release of active molecules. This medicine could be a game changer for people who suffer from chronic-neuropathic pain.

About GBS Global Biopharma, Inc.

GBS Global Biopharma, Inc, is a cannabinoid medicine development company located in Ottawa, Canada. Cannabinoid medicine is new science featuring 480+ active ingredients modulating GPCR and Ionotropic receptors involved in many disease conditions and notably those with no treatment or related to opioid addiction. GBS Global proprietary HTS/in Silico platform generates APIs for medical cannabis, nutraceutical supplement and prescription drug markets. The company currently has Rx programs in late pre-clinical and OTC programs at the formulation stage. GBS is working with nanotech time-released and rapid dissolve technology for effective oral delivery of their formulations.  To learn more, go to: https://gbsglobalbiopharma.com.

About the National Research Council Canada

Recognized globally for research and innovation, Canada’s NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. As home to Canada’s national research laboratories, the NRC undertakes and promotes research and development in support of the Canadian science and technology community, in matters affecting the design, manufacture, performance, use and safety of its science and technology.

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: https://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: chronic neuropathic painGB Sciences Inc.GBS Global Biopharma Inc.OTC:GBLX

Get Real-Time Updates from The Daily Marijuana Observer

Unsubscribe

Related Posts

Marijuana Stocks - Losers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Losers – Tuesday, October 15, 2019

October 15, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Wednesday, October 9, 2019

October 9, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Monday, September 16, 2019

September 16, 2019
Zenabis Global Inc. Announces Transition of Chief Executive Officer with Appointment of Kevin Coft
Executives

GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

August 28, 2019
Marijuana Stocks - Losers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Losers – Monday, August 12, 2019

August 12, 2019
Namaste's CannMart Signs Supply Agreements with the Ontario & Saskatchewan Provincial Agencies
Illinois

Illinois Further Accelerates Growth of Medical-Use Cannabis Program with Permanent and Expanding Qualifying Conditions Including Chronic Pain

August 12, 2019
Load More
Next Post
Jefferies Financial Group Inc. Cannabis Investment News

Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🔎 Search Marijuana Stocks

🔥 Trending

  • Walmart E-Store Now Sells CBD Products

    You Can Now Buy CBD on Walmart.com

    16 shares
    Share 6 Tweet 4
  • 5 Law Firms Launch Investigations into Aurora Cannabis Inc. for Securities Violations

    252 shares
    Share 101 Tweet 63
  • Post Malone Launches Shaboink Hemp Pre-Rolls, Announces Partnership With Icon Farms And Sherbinskis

    13 shares
    Share 5 Tweet 3
  • 2 Unilever Brands Expected to Unveil Hemp and CBD Line Extensions

    13 shares
    Share 5 Tweet 3
  • 5 Benefits of CBD—Explained by a Doctor

    506 shares
    Share 202 Tweet 127

📰 Recent News

  • Origin House Announces Significant Support to date for Pending Transaction with Cresco Labs
  • iAnthus Subsidiary CBD For Life Continues to Expand National Reach for Holiday Season
  • Organigram Receives Licensing for Chocolate Production and Packaging Area; Increased Production, Drying and Other Post-Harvesting Areas
  • Tilray, Inc. Completes Merger With Privateer Holdings, Inc.
  • MediPharm Labs Receives First GMP Certification, Now Permitted to Serve Global Medical Cannabis Market
Facebook Twitter Instagram LinkedIn Youtube

Memberships & Subscriptions

  • 📊 Compare Free vs. PRO
  • 🧾 Register for PRO
  • 🔓 PRO Login
  • 🔒 PRO Logout

News by Region

  • 🇺🇸 United States
  • 🇨🇦 Canada
  • 🇬🇧 United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Tools & Resources

  • 📅 Calendar
  • 📊 Databases
  • 📇 Directories
  • 🗣️ Forums
  • 📙 Glossary
  • 🔔 RSS Feeds
  • 📺 Videos

Find Business Services

  • ⚖️ Attorneys & Law Firms
  • 📊 Accountants & Accounting Firms
  • 💡 Consultants & Consulting Firms
  • 📲 Marketing Agencies & Firms

Advertise

  • 👀 Advertise
  • 📣 DMO Newswire
  • 📇 List in Our Databases

More

  • 📍 About MJobserver.com
  • ☎️ Contact Us
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy

© 2018 D.M.O. Holdings Corp. - DMOholdings.com DISCLAIMER: DMO Holdings Corp., which owns MJobserver.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies

© 2018 D.M.O. Holdings Corp. - DMOholdings.com DISCLAIMER: DMO Holdings Corp., which owns MJobserver.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.